Table 1.
Datasets used in this study*
| Dataset | Accession ID | Reference | Platform | Number of samples | Stage IV, % | Suboptimal debulked, % | Median survival, mo. | Median follow-up, mo. | Censoring, % | Median age | Time period |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bentink et al. 2012 | E-MTAB-386 | (6) | Illumina HumanRef-8 v2 | 127†,‡ | 15 | 22|| | 42 | 53 | 43 | 66 | 1999–2006 |
| Partheen et al. 2006 | GSE12418 | (19) | Custom | 54† | 0 | 76¶ | Short-term (<3 y) vs long-term survival (>7 y) information only | 60 | 1993–1999 | ||
| Crijns et al. 2009 | GSE13876 | (10) | Operon Human v3 | 157† | — | — | 25 | 72 | 28 | 60 | 1990–2003 |
| Yoshihara et al. 2010 | GSE17260 | (15) | Agilent G4112a | 84†,‡ | 17 | 54|| | 51 | 46 | 55 | — | — |
| Mok et al. 2009 | GSE18520 | (13) | Affymetrix U133 Plus 2.0 | 53† | 0 | — | 25 | 140 | 23 | — | 1990– 2000 |
| Konstantinopoulos et al. 2010 | GSE19829 | (30) | Affymetrix U95 v2 | 42† | — | — | 45 | 50 | 45 | — | — |
| Bonome et al. 2008 | GSE26712 | (8) | Affymetrix U133a | 185† | 19 | 51|| | 46 | 90 | 30 | 63 | 1990– 2003 |
| Gillet et al. 2012 | GSE30009 | (28) | TaqManqRT-PCR 380 | 93† | 18 | 22|| | 41 | 53 | 45 | 61 | 1995–2007 |
| Yoshihara et al. 2012 | GSE32062 | (16) | Agilent G4112a | 91†,‡ | 32 | 69|| | 104 | 56 | 56 | — | 1997–2010 |
| Tothill et al. 2008 | GSE9891 | (63) | Affymetrix U133 Plus 2.0 | 140† | 8 | 37|| | 40 | 40 | 49 | 59 | 1992–2006 |
| Dressman et al. 2007# | — | (29) | Affymetrix U133a | 59† | 15 | 44|| | 42 | 94 | 39 | — | — |
| TCGA 2011 | — | (9) | Affymetrix HT U133a | 413†,‡ | 16 | 72¶ | 41 | 54 | 44 | 59 | 1992–2009 |
| TCGA 2011 early-stage | — | (9) | Affymetrix HT U133a | 27‡,§ | 0 | 26¶ | 70 | 37 | 73 | 62 | 1992–2009 |
* No value is given for datasets for which the corresponding clinical characteristic was not available (columns Stage IV, Subopt. Debulking, Median Age, and Time Period) or for datasets not deposited in the NCBI Gene Expression Omnibus or in the EMBL-EBI ArrayExpress (column Accession ID). TCGA = The Cancer Genome Atlas.
† Only Federation of Gynecology and Obstetrics (FIGO) stage III+IV, high-grade (grade 3), serous histology.
‡ Samples already included in other studies or duplicated within the study were removed (Supplementary Table 1, available online).
§ Only FIGO stage I+II, high-grade, serous subtype.
|| Suboptimal cytoreduction defined as residual tumor mass greater than 1cm.
¶ Suboptimal cytoreduction defined as presence of macroscopic residual tumor.
# Article was retracted because of a misalignment of genomic and survival data; the corrected data were used.